• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫原性细胞死亡诱导剂联合 PD-1 阻断作为直肠癌新辅助治疗。

Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer.

机构信息

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Oncoimmunology. 2024 Oct 17;13(1):2416558. doi: 10.1080/2162402X.2024.2416558. eCollection 2024.

DOI:10.1080/2162402X.2024.2416558
PMID:39429516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11487966/
Abstract

Immuno-oncological cancer management is shifting to neoadjuvant treatments. In patients with gastrointestinal cancers, particularly locally advanced rectal cancer, neoadjuvant chemoimmunotherapy often induce complete responses, hence avoiding surgical intervention. Recent clinical trials indicate that combinations of oxaliplatin-based chemotherapy and PD-1/PD-L1-targeting immunotherapy can be safely administered before surgery with curative intent.

摘要

免疫肿瘤学癌症治疗正在向新辅助治疗转变。对于胃肠道癌症患者，特别是局部晚期直肠癌患者，新辅助化疗免疫治疗通常可诱导完全缓解，从而避免手术干预。最近的临床试验表明，奥沙利铂为基础的化疗和 PD-1/PD-L1 靶向免疫治疗的联合治疗可以在有治愈意图的手术前安全使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aed3/11487966/65b57bfafd04/KONI_A_2416558_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aed3/11487966/65b57bfafd04/KONI_A_2416558_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aed3/11487966/65b57bfafd04/KONI_A_2416558_F0001_OC.jpg

相似文献

1
Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer.免疫原性细胞死亡诱导剂联合 PD-1 阻断作为直肠癌新辅助治疗。
Oncoimmunology. 2024 Oct 17;13(1):2416558. doi: 10.1080/2162402X.2024.2416558. eCollection 2024.
2
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer.PD-1 阻断是局部晚期直肠癌新辅助放化疗的一种有前途的治疗方法。
Cancer Cell. 2024 Sep 9;42(9):1489-1491. doi: 10.1016/j.ccell.2024.08.003. Epub 2024 Aug 29.
3
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.纳米胶束保护紫杉醇的免疫激活作用，并使肿瘤对抗 PD-1 免疫治疗敏感。
Theranostics. 2020 Jul 9;10(18):8382-8399. doi: 10.7150/thno.45391. eCollection 2020.
4
Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study.新辅助动脉化疗栓塞联合 PD-1 抑制剂治疗局部进展期直肠癌（NECI 研究）：一项 II 期研究方案。
BMJ Open. 2023 Mar 13;13(3):e069401. doi: 10.1136/bmjopen-2022-069401.
5
Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.新辅助 PD-(L)1 阻断联合铂类化疗治疗潜在可切除的驱动基因阳性非小细胞肺癌。
World J Surg Oncol. 2024 Jun 18;22(1):159. doi: 10.1186/s12957-024-03434-1.
6
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial.新辅助放化疗联合或不联合 PD-1 抗体信迪利单抗治疗错配修复蛋白阳性局部晚期直肠癌的随机临床试验
Cancer Cell. 2024 Sep 9;42(9):1570-1581.e4. doi: 10.1016/j.ccell.2024.07.004. Epub 2024 Aug 1.
7
Neoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinical advances.基于 PD-1/L1 抑制剂的胃肠肿瘤新辅助免疫治疗：原理和临床进展综述。
Int J Surg. 2024 Jun 1;110(6):3707-3722. doi: 10.1097/JS9.0000000000001357.
8
Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.新辅助 PD-1/PD-L1 抑制剂治疗可切除头颈部癌症：系统评价和荟萃分析。
JAMA Otolaryngol Head Neck Surg. 2021 Oct 1;147(10):871-878. doi: 10.1001/jamaoto.2021.2191.
9
[Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].程序性死亡蛋白1（PD-1）抗体联合全新辅助放化疗治疗具有高危因素的局部进展期中低位直肠癌的短期疗效
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Nov 25;24(11):998-1007. doi: 10.3760/cma.j.cn441530-20210927-00386.
10
Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy.靶向新型调控性细胞死亡：抗 PD-1/PD-L1 癌症免疫治疗中的铁死亡、细胞焦亡和坏死性凋亡。
Cell Prolif. 2024 Aug;57(8):e13644. doi: 10.1111/cpr.13644. Epub 2024 Apr 9.

引用本文的文献

1
Global research trends in tryptophan metabolism and cancer: a bibliometric and visualization analysis (2005-2024).色氨酸代谢与癌症的全球研究趋势：文献计量与可视化分析（2005 - 2024年）
Front Oncol. 2025 Jul 1;15:1621666. doi: 10.3389/fonc.2025.1621666. eCollection 2025.

本文引用的文献

1
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).基于免疫治疗的总新辅助治疗在熟练错配修复或微卫星稳定局部晚期直肠癌中的随机 II 期试验（TORCH）。
J Clin Oncol. 2024 Oct;42(28):3308-3318. doi: 10.1200/JCO.23.02261. Epub 2024 Jul 1.
2
Targeting immunogenic cell stress and death for cancer therapy.针对免疫原性细胞应激和死亡的癌症治疗。
Nat Rev Drug Discov. 2024 Jun;23(6):445-460. doi: 10.1038/s41573-024-00920-9. Epub 2024 Apr 15.
3
Immunosurveillance in clinical cancer management.
临床癌症管理中的免疫监测。
CA Cancer J Clin. 2024 Mar-Apr;74(2):187-202. doi: 10.3322/caac.21818. Epub 2023 Oct 25.
4
Publisher Correction: The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells.出版商更正：自然杀伤细胞受体NKp46识别内质网应激细胞上的胞外钙网蛋白。
Nature. 2023 Jun;618(7964):E17. doi: 10.1038/s41586-023-06151-z.
5
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer.PD-1 阻断与基于奥沙利铂的化疗联合应用具有协同作用，而非基于顺铂的化疗。
Oncoimmunology. 2022 Jun 24;11(1):2093518. doi: 10.1080/2162402X.2022.2093518. eCollection 2022.
6
Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).多中心、随机、III 期临床试验：短期放疗联合化疗与长程放化疗治疗局部进展期直肠癌（STELLAR）。
J Clin Oncol. 2022 May 20;40(15):1681-1692. doi: 10.1200/JCO.21.01667. Epub 2022 Mar 9.
7
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.短程放疗联合化疗后行全直肠系膜切除术（TME）与术前放化疗、TME 及辅助化疗在局部进展期直肠癌（RAPIDO）中的应用：一项随机、开放标签、3 期临床试验。
Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7.
8
Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy.硫链丝菌素通过诱导自噬提高免疫化疗的疗效。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000462.
9
The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8 T cells.嘌呤能受体 P2RX7 指导长寿记忆性 CD8 T 细胞的代谢适应性。
Nature. 2018 Jul;559(7713):264-268. doi: 10.1038/s41586-018-0282-0. Epub 2018 Jul 4.
10
Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.长程基于奥沙利铂的术前放化疗与 5×5 Gy 和巩固化疗治疗 cT4 或固定 cT3 直肠癌：一项随机 III 期研究的结果。
Ann Oncol. 2016 May;27(5):834-42. doi: 10.1093/annonc/mdw062. Epub 2016 Feb 15.